Nxera Pharma

Historical price data

Nxera Pharma is a Tokyo-based, publicly traded biopharmaceutical company with a mission to deliver transformative medicines by exploiting its proprietary expertise in G protein-coupled receptor (GPCR) structure-based drug design. The company has successfully evolved from a technology licensing model into a robust, pipeline-driven enterprise with 16+ assets, underpinned by its StaR® technology platform and a dual-hub operational model spanning Japan and the UK. Its strategy focuses on advancing internal neuroscience and immuno-oncology candidates while generating significant value through strategic partnerships with major global pharmaceutical companies, positioning it as a key player in the next generation of GPCR-targeted therapeutics.

Proprietary StaR® (Stabilized Receptor) platform enabling structure-based drug design for historically intractable G protein-coupled receptors (GPCRs), accelerating the discovery of novel small molecules and biologics.

Nxera is the clear leader in proprietary GPCR structure-based drug discovery, as evidenced by its elite partner roster. Therapeutically, it faces broad competition across neuroscience and oncology but is differentiated by its ability to generate novel chemical matter against previously untargetable receptors, creating potential new drug classes.